Familial hypercholesterolaemia
KEYWORDS: people, diagnosis, quality, statement, data, treatment, testing, clinical, children, specialist, hypercholesterolaemia, familial hypercholesterolaemia, clinical diagnosis, familial, source

a specialist with expertise in FH or a GP through a shared care arrangement. [Adapted from NICE's guideline on familial hypercholesterolaemia, recommendations 1.3.1.2 to 1.3.1.6, 1.3.1.11, and terms used in this guideline] Equality and diversity considerations The statement has been restricted to adults only because there is currently no evidence on which to base any specific target for lowering LDL-C in children and young people under 16 years. However, lipid-modifying drug treatment should be considered by the age of 10 years in line with NICE's guideline on familial hypercholesterolaemia. Women with FH should be advised that lipid-modifying drug treatment should not be taken if they are planning to conceive or during pregnancy because of the risk of fetal abnormality. Women should be advised that lipid-modifying drug treatment should be stopped 3 months before they attempt to conceive. Women with FH should be advised about the potential risks and benefits of re-starting lipid-modifying drug treatment for the mother and breastfed infant. Resins are the only lipid-modifying drug treatment that should be considered during breastfeeding. Quality statement 7: Drug treatment in children Quality statement Children with familial hypercholesterolaemia (FH) are assessed for lipid-modifying drug treatment by a specialist with expertise in FH
